Novartis (NVS) to Release Earnings on Tuesday

Novartis (NYSE:NVSGet Rating) is set to release its earnings data before the market opens on Tuesday, April 26th. Analysts expect Novartis to post earnings of $1.46 per share for the quarter.

Novartis (NYSE:NVSGet Rating) last announced its earnings results on Wednesday, February 2nd. The company reported $1.40 earnings per share for the quarter, missing the consensus estimate of $1.44 by ($0.04). Novartis had a net margin of 46.27% and a return on equity of 24.57%. The business had revenue of $13.23 billion for the quarter, compared to the consensus estimate of $13.25 billion. During the same period in the previous year, the firm earned $1.34 EPS. The firm’s revenue was up 3.6% on a year-over-year basis. On average, analysts expect Novartis to post $6 EPS for the current fiscal year and $7 EPS for the next fiscal year.

NVS opened at $92.26 on Tuesday. Novartis has a one year low of $79.09 and a one year high of $95.17. The company has a debt-to-equity ratio of 0.34, a quick ratio of 1.29 and a current ratio of 1.51. The stock’s fifty day moving average is $87.15 and its 200-day moving average is $85.40. The company has a market capitalization of $206.36 billion, a PE ratio of 8.66, a P/E/G ratio of 2.61 and a beta of 0.55.

The company also recently disclosed an annual dividend, which was paid on Thursday, March 17th. Stockholders of record on Wednesday, March 9th were paid a $1.175 dividend. This represents a dividend yield of 1.36%. The ex-dividend date of this dividend was Tuesday, March 8th. Novartis’s dividend payout ratio is presently 20.28%.

A number of hedge funds and other institutional investors have recently modified their holdings of the business. Keudell Morrison Wealth Management grew its stake in Novartis by 7.3% in the third quarter. Keudell Morrison Wealth Management now owns 3,947 shares of the company’s stock valued at $323,000 after purchasing an additional 268 shares in the last quarter. 1832 Asset Management L.P. grew its stake in Novartis by 2.5% in the fourth quarter. 1832 Asset Management L.P. now owns 12,979 shares of the company’s stock valued at $1,154,000 after purchasing an additional 313 shares in the last quarter. EP Wealth Advisors LLC grew its stake in Novartis by 5.0% in the fourth quarter. EP Wealth Advisors LLC now owns 8,484 shares of the company’s stock valued at $742,000 after purchasing an additional 406 shares in the last quarter. KB Financial Partners LLC acquired a new stake in shares of Novartis in the fourth quarter worth about $36,000. Finally, BNP Paribas Arbitrage SA lifted its position in shares of Novartis by 10.7% in the third quarter. BNP Paribas Arbitrage SA now owns 5,174 shares of the company’s stock worth $423,000 after buying an additional 502 shares during the last quarter. Hedge funds and other institutional investors own 9.72% of the company’s stock.

A number of analysts have recently commented on the company. StockNews.com assumed coverage on Novartis in a research note on Thursday, March 31st. They issued a “strong-buy” rating on the stock. Citigroup started coverage on Novartis in a report on Monday, January 10th. They issued a “buy” rating on the stock. Stifel Nicolaus started coverage on Novartis in a report on Monday, February 28th. They issued a “hold” rating on the stock. UBS Group lifted their target price on Novartis from CHF 84 to CHF 85 in a report on Friday, April 8th. Finally, Societe Generale decreased their target price on Novartis from CHF 107 to CHF 105 in a report on Thursday, February 3rd. Two equities research analysts have rated the stock with a sell rating, seven have given a hold rating, five have assigned a buy rating and one has assigned a strong buy rating to the company’s stock. According to data from MarketBeat.com, the stock presently has an average rating of “Hold” and a consensus target price of $89.33.

About Novartis (Get Rating)

Novartis AG researches, develops, manufactures, and markets healthcare products worldwide. The company operates through two segments, Innovative Medicines and Sandoz. The Innovative Medicines segment offers prescription medicines for patients and healthcare providers. It also provides ophthalmology, neuroscience, immunology, hepatology, dermatology, respiratory, cardiovascular, renal, and metabolism medicine products.

See Also

Earnings History for Novartis (NYSE:NVS)

Receive News & Ratings for Novartis Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Novartis and related companies with MarketBeat.com's FREE daily email newsletter.